BONUSCAP-ZERTIFIKAT - BIONTECH ADR Stock

Certificat

DE000HD42Y26

Real-time Boerse Frankfurt Warrants 05:13:23 2024-05-23 EDT
146.2 EUR +1.39% Intraday chart for BONUSCAP-ZERTIFIKAT - BIONTECH ADR
Current month+14.25%
1 month+16.59%
Date Price Change
24-05-23 146.2 +1.39%
24-05-22 144.2 +4.39%
24-05-21 138.1 -0.98%
24-05-20 139.5 +0.06%
24-05-17 139.4 +0.47%

Real-time Boerse Frankfurt Warrants

Last update May 23, 2024 at 05:13 am

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer UniCredit UniCredit
WKN HD42Y2
ISINDE000HD42Y26
Date issued 2024-03-22
Strike 150 $
Maturity 2024-09-20 (121 Days)
Parity 1 : 1
Emission price 126.5
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 146.2
Lowest since issue 115.1
Spread 0.56
Spread %0.38%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
94.41 EUR
Average target price
105.4 EUR
Spread / Average Target
+11.62%
Consensus